Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies

Larry S. Liebovitch, Nicholas Tsinoremas, Abhijit Pandya

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Drugs designed for a specific target are always found to have multiple effects. Rather than hope that one bullet can be designed to hit only one target, nonlinear interactions across genomic and proteomic networks could be used to design Combinatorial Multi-Component Therapies (CMCT) that are more targeted with fewer side effects. We show here how computational approaches can be used to predict which combinations of drugs would produce the best effects. Using a nonlinear model of how the output effect depends on multiple input drugs, we show that an artificial neural network can accurately predict the effect of all 215 = 32,768 combinations of drug inputs using only the limited data of the output effect of the drugs presented one-at-a-time and pairs-at-a-time.

Original languageEnglish (US)
Article number11
JournalNonlinear Biomedical Physics
Volume1
DOIs
StatePublished - Aug 30 2007
Externally publishedYes

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering
  • Computer Science Applications
  • Control and Optimization

Fingerprint Dive into the research topics of 'Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies'. Together they form a unique fingerprint.

  • Cite this